search
Back to results

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251)

Primary Purpose

Unresectable Hepatocellular Carcinoma

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Atezolizumab
Lenvatinib
Sorafenib
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Unresectable Hepatocellular Carcinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/ cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients.
  • Disease progression following prior atezolizumab plus bevacizumab combination treatment for HCC, for at least 4 consecutive treatment cycles, and 2 subsequent tumor assessments. It is required that at least 1 tumor assessment shows either stable disease (SD), partial response (PR), or complete response (CR).
  • At least one measurable (per RECIST v1.1) target lesion that has not been previously treated with local therapy or, if the target lesion is within the field of previous local therapy, has subsequently progressed in accordance with RECIST v1.1.
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 within 7 days prior to randomization
  • Child-Pugh class A within 7 days prior to randomization
  • Adequate hematologic and end-organ function

Exclusion Criteria:

  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
  • History of leptomeningeal disease
  • History of hepatic encephalopathy, preceding 6 months, unresponsive to therapy within 3 days
  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death

Sites / Locations

  • Medizinische Universität Innsbruck; Universitätsklinik für Innere Medizin IRecruiting
  • Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMURecruiting
  • Universitätsklinikum St. Pölten; Innere Medizin 2Recruiting
  • Klinik Favoriten; Abteilung für ChirurgieRecruiting
  • ImeldaziekenhuisRecruiting
  • AZ KLINA
  • Hospital ErasmeRecruiting
  • Cliniques Universitaires St-Luc
  • UZ GentRecruiting
  • UZ Leuven
  • AZ Delta (Campus Rumbeke)Recruiting
  • Hospital Sao Rafael - HSR
  • Sociedade beneficente de senhoras Hospital Sirio LibanesRecruiting
  • Hospital Felicio RochoRecruiting
  • Clinicas Oncologicas Integradas - COIRecruiting
  • Hospital Moinhos de VentoRecruiting
  • Hospital Sao Lucas - PUCRSRecruiting
  • YNOVA Pesquisa ClinicaRecruiting
  • Centro Paulista de OncologiaRecruiting
  • Beneficencia Portuguesa de Sao PauloRecruiting
  • Multiprofile Hospital for Active Treatment Uni Hospital; Department of medicinal oncologyRecruiting
  • Complex Oncological Center - Plovdiv, EOOD; Second Internal DepartmentRecruiting
  • MHAT Sveta Sofia; Department of medical oncologyRecruiting
  • SHATOD Dr. Marko Antonov Markov-Varna, EOOD; Department of Medicinall Onchotherapy and PalliativeRecruiting
  • Tom Baker Cancer Centre-CalgaryRecruiting
  • Cross Cancer InstituteRecruiting
  • Juravinski Cancer CentreRecruiting
  • Princess Margaret Cancer CenterRecruiting
  • Centro de Estudios Clínicos SAGARecruiting
  • Hospital Clinico de La Universidad de Chile J.J.A.; Oncologia
  • Pontificia Universidad Catolica de Chile; Clinica San Carlos de Apoquindo
  • The Fifth Medical Center of People's Liberation Army General HospitalRecruiting
  • Peking University People's HospitalRecruiting
  • Hunan Cancer HospitalRecruiting
  • West China Hospital - Sichuan UniversityRecruiting
  • Sichuan Provincial Cancer Hospital
  • Fujian Provincial HospitalRecruiting
  • The First Affiliated Hospital, Sun Yat-sen UniversityRecruiting
  • Sun Yet-sen University Cancer CenterRecruiting
  • Nanfang Hospital, Southern Medical UniversityRecruiting
  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
  • Harbin Medical University Cancer HospitalRecruiting
  • Anhui Province Cancer Hospital
  • Shandong Provincial HospitalRecruiting
  • Shandong Cancer HospitalRecruiting
  • Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)Recruiting
  • Zhongshan Hospital Fudan UniversityRecruiting
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of MedicineRecruiting
  • Shengjing Hospital of China Medical UniversityRecruiting
  • Tianjin Cancer HospitalRecruiting
  • Tongji Hospital Tongji Medical College Huazhong University of Science and TechnologyRecruiting
  • Clinica CIMCARecruiting
  • ICIMED Instituto de Investigación en Ciencias Médicas
  • Clinical Hospital Centre ZagrebRecruiting
  • North Estonia Medical Centre, Oncology and hematology Clinic; Department of ChemotherapyRecruiting
  • Tartu University Hospital; Clinic of Hematology and OncologyRecruiting
  • Docrates Cance Center; DocratesRecruiting
  • TAYS Radius rakennus; onkologinen lääketutkimusyksikköRecruiting
  • Turku Uni Central Hospital; Oncology ClinicsRecruiting
  • CHU Grenoble Sud; Service hépato-gastroentérologieRecruiting
  • CHRU de Lille - Hopital Claude Huriez
  • Aphm; Cpcet
  • CH Saint Eloi
  • CHU de Nantes - Hotel DieuRecruiting
  • CHU Nice - Hôpital de l'Archet 2; service Hepato gastro enterologieRecruiting
  • APHP - Hopital Saint Antoine
  • CHU Bordeaux
  • Centre Eugene Marquis; Service d'oncologie; Direction de la Recherche CliniqueRecruiting
  • CHU de Toulouse - Hôpital Rangueil
  • Hopitaux de Brabois - Gastro-Entereologie
  • Hopital Paul Brousse; Centre Hepatologie Biliaire
  • Klinikum Esslingen; Allg. Innere Med., Onkologie, Hämatologie, Gastroenterologie und InfektiologieRecruiting
  • Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik IRecruiting
  • Med. Hochschule Hannover; GastroenterologieRecruiting
  • Uniklinik Mainz; I. Medizinische KlinikRecruiting
  • Universität Tübingen; Med. Klinik; Innere Medizin IRecruiting
  • Universitätsklinikum Ulm; Zentrum für Innere Medizin Klinik für Innere Medizin IRecruiting
  • Laiko General Hospital Athen; Uni Clinic of GastrenterologyRecruiting
  • Agioi Anargiroi Hospital of Kifissia; University Internal Medicine ClinicRecruiting
  • Anticancer Hospital of Thessaloniki " Theagenio"Recruiting
  • Hippokratio Hospital; 4Th Internal Medicine DptRecruiting
  • Rambam Health Care Campus; OncologyRecruiting
  • Rabin Medical Center; Oncology DeptRecruiting
  • Sourasky Medical Center; Oncology DepartmentRecruiting
  • Fondazione Pascale; U.O. Sperimentazioni ClinicheRecruiting
  • Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia MedicaRecruiting
  • Ospedale del Mare; UOC di Oncologia
  • A.O. S. Orsola Malpighi; Ambulatorio Epatocarcinoma (Bolondi)Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCSRecruiting
  • Azienda Ospedaliera San Camillo ForlaniniRecruiting
  • Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia
  • Azienda Ospedaliera Ordine Mauriziano di TorinoRecruiting
  • A.O.U. Policlinico Paolo Giaccone; Gastroenterologia ed EpatologiaRecruiting
  • Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1Recruiting
  • Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2Recruiting
  • IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
  • Fujita Health University HospitalRecruiting
  • Chiba University HospitalRecruiting
  • National Cancer Center Hospital EastRecruiting
  • Kurume University HospitalRecruiting
  • Hiroshima University Hospital
  • Japanese Red Cross Society Himeji HospitalRecruiting
  • Yokohama City University Medical CenterRecruiting
  • Osaka University HospitalRecruiting
  • Kindai University HospitalRecruiting
  • Jichi Medical University HospitalRecruiting
  • Toranomon HospitalRecruiting
  • Japanese Red Cross Musashino HospitalRecruiting
  • National Cancer Center
  • CHA Bundang Medical CenterRecruiting
  • Severance Hospital, Yonsei University Health System
  • Samsung Medical CenterRecruiting
  • Uni Malaya Medical Center; Clinical Oncology Unit, Menara TimurRecruiting
  • Institute Kanser Negara (IKN)Recruiting
  • Beacon International Specialist Centre; Clinical Research Department, Level 2
  • Cebu Doctors' University Hospital; Research OfficeRecruiting
  • Makati Medical CenterRecruiting
  • The Medical City; Cancer CenterRecruiting
  • FSBI "National Medical Research Center of Oncology N.N. Blokhin?
  • Moscow City Oncology Hospital #62; Outpatient Care CenterRecruiting
  • Group of companies "Medci"Recruiting
  • I.M.Sechenov First Moscow State Medical University (1st MSMU)Recruiting
  • Clinical Hospital Lapino (LLC Haven)Recruiting
  • LLC "Oncology scientific centre"Recruiting
  • University Medical Center Ljubljana; Clinical Dept. of GastroenterologyRecruiting
  • Corporacio Sanitaria Parc Tauli; Servicio de HepatologiaRecruiting
  • Hospital Son Llatzer; Servicio de OncologiaRecruiting
  • Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de OncologiaRecruiting
  • Clinica Universitaria de Navarra; Servicio de HepatologiaRecruiting
  • Hospital Universitari Vall d'Hebron; Servicio de HepatologiaRecruiting
  • Hospital Universitario Reina Sofia; Servicio de HepatologiaRecruiting
  • Hospital General Universitario Gregorio Marañon; Servicio de Aparato DigestivoRecruiting
  • Clinica Universidad de Navarra Madrid; Servicio de OncologíaRecruiting
  • Hospital Clinico San Carlos; Servicio de OncologiaRecruiting
  • START Madrid. Centro Integral Oncologico Clara Campal; CIOCCRecruiting
  • Hospital Universitario la Fe; Servicio de OncologiaRecruiting
  • Hospital Universitario Miguel Servet; Servicio OncologiaRecruiting
  • Inselspital Bern Medizin GastroenterologieRecruiting
  • Universitätsspital Zürich Medizin Gastroenterologie; Klinik für Gastroenterologie und HepatologieRecruiting
  • Chi-Mei Medical Centre; Hematology & OncologyRecruiting
  • National Taiwan University Hospital; OncologyRecruiting
  • Chulalongkorn Hospital; Medical Oncology
  • Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. OncologyRecruiting
  • Adana Ac?badem Hospital Oncology Department
  • Memorial Ankara Hastanesi
  • Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi OnkolojiRecruiting
  • Uludag Uni Hospital; OncologyRecruiting
  • Medipol Mega Üniversite Hastanesi GöztepeRecruiting
  • Ege Uni Medical Faculty Hospital; Oncology Dept
  • Hacettepe Uni Medical Faculty Hospital; Oncology DeptRecruiting
  • Ac?badem Altunizade Hastanesi; OncologyRecruiting
  • Queen Elizabeth Hospital; Hepatobiliary UnitRecruiting
  • The Clatterbridge Cancer Centre NHS Foundation TrustRecruiting
  • Royal Free HospitalRecruiting
  • King College Hospital NHS Foundation Trust
  • Hammersmith Hospital; Clinical trials unitRecruiting
  • Christie Hospital Nhs Trust; Medical OncologyRecruiting
  • Freeman Hospital; Gastroenterology & Liver UnitRecruiting
  • Churchill Hospital; Department of OncologyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Atezolizumab + Lenvatinib or Sorafenib

Lenvatinib or Sorafenib

Arm Description

Participants will receive atezolizumab plus lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Participants will receive lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Outcomes

Primary Outcome Measures

Overall Survival (OS)
Overall survival (OS) is defined as the time from randomization into the study to death from any cause.

Secondary Outcome Measures

Progression Free Survival (PFS)
Progression free survival (PFS) is defined as the time from randomization into the study to the first occurrence of disease progression or death from any cause (whichever occurs first).
Confirmed Objective Response Rate (ORR)
Confirmed Objective Response Rate (ORR) is defined as the proportion of patients with a best response of either complete or partial response.
Time to Progression (TTP)
Time to Progression (TTP) is defined as the time from randomization to the first occurrence of disease progression.
Duration of Response (DOR)
Duration of Response (DOR) is defined as the time from the first occurrence of a documented confirmed objective response to disease progression or death from any cause (whichever occurs first).
Time to deterioration (TTD)
Time to deterioration (TTD), of health-related quality of life (HRQoL), is defined as the time from randomization to first deterioration (decrease from baseline of ≥ 10 points) maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks (if Cycle 1-6) or 6 weeks (if after Cycle 6) in the following European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30(EORTC QLQC30) scales (separately): physical function, role function, and GHS/QoL.
Percentage of Participants With Adverse Events
Percentage of Participants With Adverse Events for Combination Treatment, Adverse Events Related to Atezolizumab, and TKI-Related Adverse Events
Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
Serum Concentration of Atezolizumab

Full Information

First Posted
February 23, 2021
Last Updated
October 13, 2023
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT04770896
Brief Title
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
Acronym
IMbrave251
Official Title
A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 26, 2021 (Actual)
Primary Completion Date
September 23, 2024 (Anticipated)
Study Completion Date
September 23, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Unresectable Hepatocellular Carcinoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
554 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Atezolizumab + Lenvatinib or Sorafenib
Arm Type
Experimental
Arm Description
Participants will receive atezolizumab plus lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Arm Title
Lenvatinib or Sorafenib
Arm Type
Active Comparator
Arm Description
Participants will receive lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Intervention Type
Drug
Intervention Name(s)
Atezolizumab
Other Intervention Name(s)
Tecentriq
Intervention Description
Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Intervention Type
Drug
Intervention Name(s)
Lenvatinib
Intervention Description
Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of < 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.
Intervention Type
Drug
Intervention Name(s)
Sorafenib
Intervention Description
Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
Primary Outcome Measure Information:
Title
Overall Survival (OS)
Description
Overall survival (OS) is defined as the time from randomization into the study to death from any cause.
Time Frame
Randomization until death from any cause (approximately 42 months)
Secondary Outcome Measure Information:
Title
Progression Free Survival (PFS)
Description
Progression free survival (PFS) is defined as the time from randomization into the study to the first occurrence of disease progression or death from any cause (whichever occurs first).
Time Frame
Randomization until the first occurrence of disease progression or death from any cause whichever occurs first (approximately 42 months)
Title
Confirmed Objective Response Rate (ORR)
Description
Confirmed Objective Response Rate (ORR) is defined as the proportion of patients with a best response of either complete or partial response.
Time Frame
Approximately 42 months
Title
Time to Progression (TTP)
Description
Time to Progression (TTP) is defined as the time from randomization to the first occurrence of disease progression.
Time Frame
Randomization until the first occurrence of disease progression (approximately 42 months)
Title
Duration of Response (DOR)
Description
Duration of Response (DOR) is defined as the time from the first occurrence of a documented confirmed objective response to disease progression or death from any cause (whichever occurs first).
Time Frame
Time from the first occurrence of a confirmed documented objective response to disease progression or death from any cause whichever occurs first (approximately 42 months)
Title
Time to deterioration (TTD)
Description
Time to deterioration (TTD), of health-related quality of life (HRQoL), is defined as the time from randomization to first deterioration (decrease from baseline of ≥ 10 points) maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks (if Cycle 1-6) or 6 weeks (if after Cycle 6) in the following European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30(EORTC QLQC30) scales (separately): physical function, role function, and GHS/QoL.
Time Frame
Randomization to first deterioration maintained for two consecutive assessments, or one assessment followed by death from any cause wthin 3 weeks or 6 weeks (approximately 42 months)
Title
Percentage of Participants With Adverse Events
Time Frame
Throughout study duration (approximately 42 months)
Title
Percentage of Participants With Adverse Events for Combination Treatment, Adverse Events Related to Atezolizumab, and TKI-Related Adverse Events
Time Frame
Throughtout study (approximately 42 months)
Title
Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
Time Frame
Throughout study (approximately 42 months)
Title
Serum Concentration of Atezolizumab
Time Frame
At pre-defined intervals from first administration of study drug to approximately 42 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/ cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients. Disease progression following prior atezolizumab plus bevacizumab combination treatment for HCC, for at least 4 consecutive treatment cycles, and 2 subsequent tumor assessments. It is required that at least 1 tumor assessment shows either stable disease (SD), partial response (PR), or complete response (CR). At least one measurable (per RECIST v1.1) target lesion that has not been previously treated with local therapy or, if the target lesion is within the field of previous local therapy, has subsequently progressed in accordance with RECIST v1.1. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 within 7 days prior to randomization Child-Pugh class A within 7 days prior to randomization Adequate hematologic and end-organ function Exclusion Criteria: Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases. History of leptomeningeal disease History of hepatic encephalopathy, preceding 6 months, unresponsive to therapy within 3 days Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Reference Study ID Number: MO42541 https://forpatients.roche.com/
Phone
888-662-6728 (U.S. and Canada)
Email
global.rochegenentechtrials@roche.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
Medizinische Universität Innsbruck; Universitätsklinik für Innere Medizin I
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Individual Site Status
Recruiting
Facility Name
Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Individual Site Status
Recruiting
Facility Name
Universitätsklinikum St. Pölten; Innere Medizin 2
City
St. Pölten
ZIP/Postal Code
3100
Country
Austria
Individual Site Status
Recruiting
Facility Name
Klinik Favoriten; Abteilung für Chirurgie
City
Wien
ZIP/Postal Code
1100
Country
Austria
Individual Site Status
Recruiting
Facility Name
Imeldaziekenhuis
City
Bonheiden
ZIP/Postal Code
2820
Country
Belgium
Individual Site Status
Recruiting
Facility Name
AZ KLINA
City
Brasschaat
ZIP/Postal Code
2930
Country
Belgium
Individual Site Status
Active, not recruiting
Facility Name
Hospital Erasme
City
Bruxelles
ZIP/Postal Code
1070
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Cliniques Universitaires St-Luc
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Active, not recruiting
Facility Name
UZ Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Name
UZ Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Active, not recruiting
Facility Name
AZ Delta (Campus Rumbeke)
City
Roeselare
ZIP/Postal Code
8800
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Hospital Sao Rafael - HSR
City
Salvador
State/Province
BA
ZIP/Postal Code
41253-190
Country
Brazil
Individual Site Status
Withdrawn
Facility Name
Sociedade beneficente de senhoras Hospital Sirio Libanes
City
Brasilia
State/Province
DF
ZIP/Postal Code
70200-730
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Hospital Felicio Rocho
City
Belo Horizonte
State/Province
MG
ZIP/Postal Code
30110-068
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Clinicas Oncologicas Integradas - COI
City
Rio De Janeiro
State/Province
RJ
ZIP/Postal Code
22290-160
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Hospital Moinhos de Vento
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90035-000
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Hospital Sao Lucas - PUCRS
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90610-000
Country
Brazil
Individual Site Status
Recruiting
Facility Name
YNOVA Pesquisa Clinica
City
Florianopolis
State/Province
SC
ZIP/Postal Code
88020-210
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Centro Paulista de Oncologia
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
04538-132
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Beneficencia Portuguesa de Sao Paulo
City
São Paulo
State/Province
SP
ZIP/Postal Code
01321-00
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Multiprofile Hospital for Active Treatment Uni Hospital; Department of medicinal oncology
City
Panagyurishte
ZIP/Postal Code
4500
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Complex Oncological Center - Plovdiv, EOOD; Second Internal Department
City
Plovdiv
ZIP/Postal Code
4004
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
MHAT Sveta Sofia; Department of medical oncology
City
Sofia
ZIP/Postal Code
1618
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
SHATOD Dr. Marko Antonov Markov-Varna, EOOD; Department of Medicinall Onchotherapy and Palliative
City
Varna
ZIP/Postal Code
9010
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Tom Baker Cancer Centre-Calgary
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4N2
Country
Canada
Individual Site Status
Recruiting
Facility Name
Cross Cancer Institute
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1Z2
Country
Canada
Individual Site Status
Recruiting
Facility Name
Juravinski Cancer Centre
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8V 5C2
Country
Canada
Individual Site Status
Recruiting
Facility Name
Princess Margaret Cancer Center
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Name
Centro de Estudios Clínicos SAGA
City
Santiago
ZIP/Postal Code
7500653
Country
Chile
Individual Site Status
Recruiting
Facility Name
Hospital Clinico de La Universidad de Chile J.J.A.; Oncologia
City
Santiago
ZIP/Postal Code
8380456
Country
Chile
Individual Site Status
Withdrawn
Facility Name
Pontificia Universidad Catolica de Chile; Clinica San Carlos de Apoquindo
City
Santiago
Country
Chile
Individual Site Status
Withdrawn
Facility Name
The Fifth Medical Center of People's Liberation Army General Hospital
City
Beijing City
ZIP/Postal Code
100039
Country
China
Individual Site Status
Recruiting
Facility Name
Peking University People's Hospital
City
Beijing
ZIP/Postal Code
100044
Country
China
Individual Site Status
Recruiting
Facility Name
Hunan Cancer Hospital
City
Changsha CITY
ZIP/Postal Code
410013
Country
China
Individual Site Status
Recruiting
Facility Name
West China Hospital - Sichuan University
City
Chengdu City
ZIP/Postal Code
610047
Country
China
Individual Site Status
Recruiting
Facility Name
Sichuan Provincial Cancer Hospital
City
Chengdu
ZIP/Postal Code
610041
Country
China
Individual Site Status
Withdrawn
Facility Name
Fujian Provincial Hospital
City
Fuzhou City
ZIP/Postal Code
350001
Country
China
Individual Site Status
Recruiting
Facility Name
The First Affiliated Hospital, Sun Yat-sen University
City
Guangzhou City
ZIP/Postal Code
510080
Country
China
Individual Site Status
Recruiting
Facility Name
Sun Yet-sen University Cancer Center
City
Guangzhou City
ZIP/Postal Code
510663
Country
China
Individual Site Status
Recruiting
Facility Name
Nanfang Hospital, Southern Medical University
City
Guangzhou
ZIP/Postal Code
510515
Country
China
Individual Site Status
Recruiting
Facility Name
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
City
Hangzhou
ZIP/Postal Code
310016
Country
China
Individual Site Status
Withdrawn
Facility Name
Harbin Medical University Cancer Hospital
City
Harbin
ZIP/Postal Code
150081
Country
China
Individual Site Status
Recruiting
Facility Name
Anhui Province Cancer Hospital
City
Hefei City
ZIP/Postal Code
230031
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Shandong Provincial Hospital
City
Jinan
ZIP/Postal Code
250021
Country
China
Individual Site Status
Recruiting
Facility Name
Shandong Cancer Hospital
City
Jinan
ZIP/Postal Code
250117
Country
China
Individual Site Status
Recruiting
Facility Name
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
City
Nanjing City
ZIP/Postal Code
210029
Country
China
Individual Site Status
Recruiting
Facility Name
Zhongshan Hospital Fudan University
City
Shanghai
ZIP/Postal Code
200032
Country
China
Individual Site Status
Recruiting
Facility Name
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
City
Shanghai
ZIP/Postal Code
200127
Country
China
Individual Site Status
Recruiting
Facility Name
Shengjing Hospital of China Medical University
City
ShenYang
ZIP/Postal Code
110004
Country
China
Individual Site Status
Recruiting
Facility Name
Tianjin Cancer Hospital
City
Tianjin
ZIP/Postal Code
300060
Country
China
Individual Site Status
Recruiting
Facility Name
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
City
Wuhan City
ZIP/Postal Code
430030
Country
China
Individual Site Status
Recruiting
Facility Name
Clinica CIMCA
City
San José
ZIP/Postal Code
10103
Country
Costa Rica
Individual Site Status
Recruiting
Facility Name
ICIMED Instituto de Investigación en Ciencias Médicas
City
San José
ZIP/Postal Code
10108
Country
Costa Rica
Individual Site Status
Active, not recruiting
Facility Name
Clinical Hospital Centre Zagreb
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Individual Site Status
Recruiting
Facility Name
North Estonia Medical Centre, Oncology and hematology Clinic; Department of Chemotherapy
City
Tallinn
ZIP/Postal Code
13419
Country
Estonia
Individual Site Status
Recruiting
Facility Name
Tartu University Hospital; Clinic of Hematology and Oncology
City
Tartu
ZIP/Postal Code
50406
Country
Estonia
Individual Site Status
Recruiting
Facility Name
Docrates Cance Center; Docrates
City
Helsinki
ZIP/Postal Code
00180
Country
Finland
Individual Site Status
Recruiting
Facility Name
TAYS Radius rakennus; onkologinen lääketutkimusyksikkö
City
Tampere
ZIP/Postal Code
33521
Country
Finland
Individual Site Status
Recruiting
Facility Name
Turku Uni Central Hospital; Oncology Clinics
City
Turku
ZIP/Postal Code
20520
Country
Finland
Individual Site Status
Recruiting
Facility Name
CHU Grenoble Sud; Service hépato-gastroentérologie
City
GRENOBLE Cedex 9
ZIP/Postal Code
38043
Country
France
Individual Site Status
Recruiting
Facility Name
CHRU de Lille - Hopital Claude Huriez
City
Lille
ZIP/Postal Code
59037
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Aphm; Cpcet
City
Marseille
ZIP/Postal Code
13385
Country
France
Individual Site Status
Active, not recruiting
Facility Name
CH Saint Eloi
City
Montpellier
ZIP/Postal Code
34295
Country
France
Individual Site Status
Active, not recruiting
Facility Name
CHU de Nantes - Hotel Dieu
City
Nantes
ZIP/Postal Code
44093
Country
France
Individual Site Status
Recruiting
Facility Name
CHU Nice - Hôpital de l'Archet 2; service Hepato gastro enterologie
City
Nice Cedex
ZIP/Postal Code
06202
Country
France
Individual Site Status
Recruiting
Facility Name
APHP - Hopital Saint Antoine
City
Paris
ZIP/Postal Code
75571
Country
France
Individual Site Status
Active, not recruiting
Facility Name
CHU Bordeaux
City
Pessac
ZIP/Postal Code
33604
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Centre Eugene Marquis; Service d'oncologie; Direction de la Recherche Clinique
City
Rennes
ZIP/Postal Code
35042
Country
France
Individual Site Status
Recruiting
Facility Name
CHU de Toulouse - Hôpital Rangueil
City
Toulouse Cedex 09
ZIP/Postal Code
31059
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hopitaux de Brabois - Gastro-Entereologie
City
Vandoeuvre-les-nancy
ZIP/Postal Code
54511
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hopital Paul Brousse; Centre Hepatologie Biliaire
City
Villejuif
ZIP/Postal Code
94804
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Klinikum Esslingen; Allg. Innere Med., Onkologie, Hämatologie, Gastroenterologie und Infektiologie
City
Esslingen
ZIP/Postal Code
73730
Country
Germany
Individual Site Status
Recruiting
Facility Name
Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I
City
Frankfurt
ZIP/Postal Code
60590
Country
Germany
Individual Site Status
Recruiting
Facility Name
Med. Hochschule Hannover; Gastroenterologie
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Individual Site Status
Recruiting
Facility Name
Uniklinik Mainz; I. Medizinische Klinik
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universität Tübingen; Med. Klinik; Innere Medizin I
City
Tübingen
ZIP/Postal Code
72076
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinikum Ulm; Zentrum für Innere Medizin Klinik für Innere Medizin I
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Individual Site Status
Recruiting
Facility Name
Laiko General Hospital Athen; Uni Clinic of Gastrenterology
City
Athens
ZIP/Postal Code
115 27
Country
Greece
Individual Site Status
Recruiting
Facility Name
Agioi Anargiroi Hospital of Kifissia; University Internal Medicine Clinic
City
Nea Kifissia
ZIP/Postal Code
14564
Country
Greece
Individual Site Status
Recruiting
Facility Name
Anticancer Hospital of Thessaloniki " Theagenio"
City
Thessaloniki
ZIP/Postal Code
54007
Country
Greece
Individual Site Status
Recruiting
Facility Name
Hippokratio Hospital; 4Th Internal Medicine Dpt
City
Thessaloniki
ZIP/Postal Code
546 42
Country
Greece
Individual Site Status
Recruiting
Facility Name
Rambam Health Care Campus; Oncology
City
Haifa
ZIP/Postal Code
3109601
Country
Israel
Individual Site Status
Recruiting
Facility Name
Rabin Medical Center; Oncology Dept
City
Petah Tikva
ZIP/Postal Code
4910000
Country
Israel
Individual Site Status
Recruiting
Facility Name
Sourasky Medical Center; Oncology Department
City
Tel-Aviv
ZIP/Postal Code
6423900
Country
Israel
Individual Site Status
Recruiting
Facility Name
Fondazione Pascale; U.O. Sperimentazioni Cliniche
City
Napoli
State/Province
Campania
ZIP/Postal Code
80100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica
City
Napoli
State/Province
Campania
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Recruiting
Facility Name
Ospedale del Mare; UOC di Oncologia
City
Napoli
State/Province
Campania
ZIP/Postal Code
80147
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
A.O. S. Orsola Malpighi; Ambulatorio Epatocarcinoma (Bolondi)
City
Bologna
State/Province
Emilia-Romagna
ZIP/Postal Code
40138
Country
Italy
Individual Site Status
Recruiting
Facility Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
City
Roma
State/Province
Lazio
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliera San Camillo Forlanini
City
Roma
State/Province
Lazio
ZIP/Postal Code
151
Country
Italy
Individual Site Status
Recruiting
Facility Name
Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20122
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Azienda Ospedaliera Ordine Mauriziano di Torino
City
Torino
State/Province
Piemonte
ZIP/Postal Code
10128
Country
Italy
Individual Site Status
Recruiting
Facility Name
A.O.U. Policlinico Paolo Giaccone; Gastroenterologia ed Epatologia
City
Palermo
State/Province
Sicilia
ZIP/Postal Code
90127
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1
City
Firenze
State/Province
Toscana
ZIP/Postal Code
50139
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2
City
Pisa
State/Province
Toscana
ZIP/Postal Code
56100
Country
Italy
Individual Site Status
Recruiting
Facility Name
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
City
Padova
State/Province
Veneto
ZIP/Postal Code
35128
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Fujita Health University Hospital
City
Aichi
ZIP/Postal Code
470-1192
Country
Japan
Individual Site Status
Recruiting
Facility Name
Chiba University Hospital
City
Chiba
ZIP/Postal Code
260-8677
Country
Japan
Individual Site Status
Recruiting
Facility Name
National Cancer Center Hospital East
City
Chiba
ZIP/Postal Code
277-8577
Country
Japan
Individual Site Status
Recruiting
Facility Name
Kurume University Hospital
City
Fukuoka
ZIP/Postal Code
830-0011
Country
Japan
Individual Site Status
Recruiting
Facility Name
Hiroshima University Hospital
City
Hiroshima
ZIP/Postal Code
734-8551
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Japanese Red Cross Society Himeji Hospital
City
Hyogo
ZIP/Postal Code
670-8540
Country
Japan
Individual Site Status
Recruiting
Facility Name
Yokohama City University Medical Center
City
Kanagawa
ZIP/Postal Code
232-0024
Country
Japan
Individual Site Status
Recruiting
Facility Name
Osaka University Hospital
City
Osaka
ZIP/Postal Code
565-0871
Country
Japan
Individual Site Status
Recruiting
Facility Name
Kindai University Hospital
City
Osaka
ZIP/Postal Code
589-8511
Country
Japan
Individual Site Status
Recruiting
Facility Name
Jichi Medical University Hospital
City
Tochigi
ZIP/Postal Code
329-0498
Country
Japan
Individual Site Status
Recruiting
Facility Name
Toranomon Hospital
City
Tokyo
ZIP/Postal Code
105-8470
Country
Japan
Individual Site Status
Recruiting
Facility Name
Japanese Red Cross Musashino Hospital
City
Tokyo
ZIP/Postal Code
180-8610
Country
Japan
Individual Site Status
Recruiting
Facility Name
National Cancer Center
City
Goyang-si
ZIP/Postal Code
10408
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
CHA Bundang Medical Center
City
Gyeonggi-do
ZIP/Postal Code
13496
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Severance Hospital, Yonsei University Health System
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Uni Malaya Medical Center; Clinical Oncology Unit, Menara Timur
City
Kuala Lumpur
State/Province
FED. Territory OF Kuala Lumpur
ZIP/Postal Code
59100
Country
Malaysia
Individual Site Status
Recruiting
Facility Name
Institute Kanser Negara (IKN)
City
Putrajaya
State/Province
FED. Territory OF Kuala Lumpur
ZIP/Postal Code
62250
Country
Malaysia
Individual Site Status
Recruiting
Facility Name
Beacon International Specialist Centre; Clinical Research Department, Level 2
City
Petaling Jaya, Selangor
State/Province
Selangor
ZIP/Postal Code
46050
Country
Malaysia
Individual Site Status
Active, not recruiting
Facility Name
Cebu Doctors' University Hospital; Research Office
City
Cebu City
ZIP/Postal Code
6000
Country
Philippines
Individual Site Status
Recruiting
Facility Name
Makati Medical Center
City
Makati City
ZIP/Postal Code
1229
Country
Philippines
Individual Site Status
Recruiting
Facility Name
The Medical City; Cancer Center
City
Pasig City
ZIP/Postal Code
1600
Country
Philippines
Individual Site Status
Recruiting
Facility Name
FSBI "National Medical Research Center of Oncology N.N. Blokhin?
City
Moscow
State/Province
Moskovskaja Oblast
ZIP/Postal Code
115478
Country
Russian Federation
Individual Site Status
Active, not recruiting
Facility Name
Moscow City Oncology Hospital #62; Outpatient Care Center
City
Moscow
State/Province
Moskovskaja Oblast
ZIP/Postal Code
125134
Country
Russian Federation
Individual Site Status
Recruiting
Facility Name
Group of companies "Medci"
City
Moskva
State/Province
Moskovskaja Oblast
ZIP/Postal Code
105229
Country
Russian Federation
Individual Site Status
Recruiting
Facility Name
I.M.Sechenov First Moscow State Medical University (1st MSMU)
City
Moskva
State/Province
Moskovskaja Oblast
ZIP/Postal Code
119991
Country
Russian Federation
Individual Site Status
Recruiting
Facility Name
Clinical Hospital Lapino (LLC Haven)
City
Yudino
State/Province
Moskovskaja Oblast
ZIP/Postal Code
143081
Country
Russian Federation
Individual Site Status
Recruiting
Facility Name
LLC "Oncology scientific centre"
City
Pesochny
State/Province
Sankt Petersburg
ZIP/Postal Code
197758
Country
Russian Federation
Individual Site Status
Recruiting
Facility Name
University Medical Center Ljubljana; Clinical Dept. of Gastroenterology
City
Ljubljana
ZIP/Postal Code
1000
Country
Slovenia
Individual Site Status
Recruiting
Facility Name
Corporacio Sanitaria Parc Tauli; Servicio de Hepatologia
City
Sabadell
State/Province
Barcelona
ZIP/Postal Code
08208
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Son Llatzer; Servicio de Oncologia
City
Palma de Mallorca
State/Province
Islas Baleares
ZIP/Postal Code
07198
Country
Spain
Individual Site Status
Recruiting
Facility Name
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
City
Santiago de Compostela
State/Province
LA Coruña
ZIP/Postal Code
15706
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinica Universitaria de Navarra; Servicio de Hepatologia
City
Pamplona/iruña
State/Province
Navarra
ZIP/Postal Code
31008
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitari Vall d'Hebron; Servicio de Hepatologia
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Reina Sofia; Servicio de Hepatologia
City
Cordoba
ZIP/Postal Code
14004
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital General Universitario Gregorio Marañon; Servicio de Aparato Digestivo
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinica Universidad de Navarra Madrid; Servicio de Oncología
City
Madrid
ZIP/Postal Code
28027
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico San Carlos; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Individual Site Status
Recruiting
Facility Name
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario la Fe; Servicio de Oncologia
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Miguel Servet; Servicio Oncologia
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Individual Site Status
Recruiting
Facility Name
Inselspital Bern Medizin Gastroenterologie
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Recruiting
Facility Name
Universitätsspital Zürich Medizin Gastroenterologie; Klinik für Gastroenterologie und Hepatologie
City
Zürich
ZIP/Postal Code
8091
Country
Switzerland
Individual Site Status
Recruiting
Facility Name
Chi-Mei Medical Centre; Hematology & Oncology
City
Tainan
ZIP/Postal Code
710
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
National Taiwan University Hospital; Oncology
City
Zhongzheng Dist.
ZIP/Postal Code
10048
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Chulalongkorn Hospital; Medical Oncology
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Individual Site Status
Active, not recruiting
Facility Name
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Adana Ac?badem Hospital Oncology Department
City
Adana
ZIP/Postal Code
01130
Country
Turkey
Individual Site Status
Active, not recruiting
Facility Name
Memorial Ankara Hastanesi
City
Ankara
ZIP/Postal Code
06520
Country
Turkey
Individual Site Status
Active, not recruiting
Facility Name
Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji
City
Bakirkoy / Istanbul
ZIP/Postal Code
34147
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Uludag Uni Hospital; Oncology
City
Bursa
ZIP/Postal Code
16059
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Medipol Mega Üniversite Hastanesi Göztepe
City
Istanbul
ZIP/Postal Code
34214
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Ege Uni Medical Faculty Hospital; Oncology Dept
City
Izmir
ZIP/Postal Code
35100
Country
Turkey
Individual Site Status
Active, not recruiting
Facility Name
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
City
Sihhiye/Ankara
ZIP/Postal Code
06230
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Ac?badem Altunizade Hastanesi; Oncology
City
Üsküdar
ZIP/Postal Code
34662
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Queen Elizabeth Hospital; Hepatobiliary Unit
City
Birmingham
ZIP/Postal Code
B15 2TH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
The Clatterbridge Cancer Centre NHS Foundation Trust
City
Liverpool
ZIP/Postal Code
L7 8YA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Royal Free Hospital
City
London
ZIP/Postal Code
NW3 2QS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
King College Hospital NHS Foundation Trust
City
London
ZIP/Postal Code
SE5 9RS
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Hammersmith Hospital; Clinical trials unit
City
London
ZIP/Postal Code
W12 0HS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Christie Hospital Nhs Trust; Medical Oncology
City
Manchester
ZIP/Postal Code
M2O 4BX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Freeman Hospital; Gastroenterology & Liver Unit
City
Newcastle Upon Tyne
ZIP/Postal Code
NE7 7DN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Churchill Hospital; Department of Oncology
City
Oxford
ZIP/Postal Code
OX3 7LE
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here ( https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Learn more about this trial

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

We'll reach out to this number within 24 hrs